Informazioni sul prodotto
- PF-07059013PF07059013PF 07059013
PF 07059013 is a novel compound that has been shown to reduce the frequency of sickled red blood cells in a dose-dependent manner. It also reduces the levels of hemoglobin S and increases the levels of hemoglobin A2. PF 07059013 is being developed for use as an oral treatment for sickle cell disease. This drug binds to hemoglobin in the same way that hydroxyurea does, but with much higher affinity and selectivity. The molecule was optimized for clinical trials, screened against other drugs, and found to have good biochemical properties.
PF 07059013 is currently undergoing clinical trials with promising results so far.
Proprietà chimiche
Richiesta tecnica su: 3D-BP180184 PF 07059013
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.
